[Consolidation therapy with high-dose cytarabine and daunorubicin for prolonged disease free survival in acute myelocytic leukemia].
In order to study the effect of consolidation therapy with high-dose cytarabine (Ara-C) and daunorubicin (DNR) for prolonged disease free survival (DFS) in acute myelocytic leukemia (AML), 51 patients with AML in remission were treated with this method. Ara-C at a dosage of 1.3g/m2 administered in 2-hour intravenous infusion every 12 hours for 10 doses. After the treatment of Ara-C, DNR was given at a daily dose of 45 mg/m2 in rapid intravenous infusion for two days. The median duration of complete remission (CR) was 32 (8.2-110) months. The duration of DFS was more than 3 years in 21 patients (41.18%) and more than 2 years in 35 (68.63%). In a control group, however, the median duration of CR was 10 months and the rates of patients with DFS more than 3 and 2 years were 12.5% and 21.8% respectively. It is shown that high-dose consolidation chemotherapy is an effective method to prolong DFS in patients with AML. Toxicities of high-dose Ara-C and DNR can be tolerated by patients with AML.
Qiau
Z
Z
Department of Hematology, Second Affiliated Hospital, Shanxi Medical College, Taiyuan.
Wang
C
C
Yang
L
L
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D003561:Cytarabine; D003630:Daunorubicin